HCPro, JustCoding Outpatient - 2020 Issue 46 (December)
Healthcare News: CMS announces billing details for new COVID-19 antibody drug
December 1st, 2020
Subscribe or sign in to view the full article.
Article Overview
This article covers CMS Medicare billing and payment information related to a newly authorized COVID-19 monoclonal antibody product and its administration. It is relevant to providers, billers, and coders handling Medicare claims for COVID-19 therapeutics. The discussion focuses on the general billing framework, payment approach, claim submission options, and the HCPCS codes tied to the product and its infusion services.
Why This Topic Matters
It helps healthcare organizations understand how Medicare is handling payment and claims processing for a new COVID-19 antibody therapy, including how the administration is billed and how free product supply affects claims.
What You Will Learn
- The Medicare billing and payment context for a COVID-19 monoclonal antibody therapy
- How CMS addresses payment when the product is supplied at no charge
- General claim submission options for administration of the antibody infusion
- Which HCPCS codes are referenced for the product and its administration
- What CMS says about the timing and framework for related Medicare guidance
Who Should Read This
- Medical coders
- Billing staff
- Revenue cycle teams
- Hospitals and outpatient providers
- Medicare compliance staff
Codes Discussed
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com